Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest German inventions Stories

2011-09-08 07:00:00

SAN FRANCISCO, Sept. 8, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that dosing began in a Phase 1 clinical study to evaluate multiple ascending doses of NKTR-181, the company's novel opioid analgesic drug candidate. NKTR-181 is in development as a once- or twice-daily oral tablet for the treatment of chronic pain, and is designed to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies....

2011-09-06 20:35:16

Doctors have been prescribing codeine for postpartum pain management for many years, and, until recently, it was considered safe to breastfeed while taking the opioid. But the death of an infant exposed to codeine through breast milk has many health care providers questioning the safety of the drug when used by breastfeeding mothers. Because of the potential risks, some doctors have begun the practice of prescribing oxycodone as an alternative to codeine; however, a new study soon to be...

2011-08-26 07:30:00

RARITAN, N.J., Aug. 26, 2011 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved NUCYNTA® ER, an oral analgesic taken twice daily, for the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. To view the multimedia assets associated with this release, please click:...

2011-08-25 07:05:00

Clinical Data Package to US FDA as Follow-Up to Initial CMC Filing SYDNEY and BEDMINSTER, N.J., Aug. 25, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today submission of its New Drug Application (NDA) clinical data package to the United States Food and Drug Administration (FDA) for MoxDuo IR, an immediate-release Dual Opioid® pain therapy comprised of a patented 3:2 fixed ratio combination of morphine and oxycodone. The NDA Chemistry,...

2011-08-04 13:33:54

Health Affairs report describes ground-breaking effort Fatal overdoses involving prescribed opioids tripled in the United States between 1999 and 2006, climbing to almost 14,000 deaths annually"”more than cocaine and heroin overdoses combined. Hospitalizations and emergency room visits related to prescription opioid pain medicines such as oxycodone (brand name Oxycontin) and hydrocodone (Vicodin) also increased dramatically in the same period. Now a report in the August issue of Health...

2011-08-02 09:00:00

LAKE FOREST, Calif., Aug. 2, 2011 /PRNewswire/ -- I-Flow, a Kimberly-Clark Health Care Company, today entered into an exclusive distribution agreement with Buffalo Supply, Inc. (BSI), whereby its flagship ON-Q® Pain Relief System products will be available on Buffalo Supply's Federal Supply Schedule. These products include ON-Q® C-bloc®, ON-Q® PainBuster®, ON-Q® Soaker Catheters,...

2011-08-01 12:57:00

LITTLE ROCK, Ark. and WILMINGTON, Del., Aug. 1, 2011 /PRNewswire/ -- More than half the people who take opioids for chronic pain are likely to still be taking the painkillers five years later, according to a new study published online July 13 in the Journal of General Internal Medicine. The article, "Long-Term Chronic Opioid Therapy Discontinuation Rates from the TROUP Study," co-authored by researchers from University of Arkansas for Medical Sciences, University of Washington and...

2011-07-28 16:00:00

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV® (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg. Cadence's announcement follows the issuance of a news release by a major manufacturer of over-the-counter (OTC) acetaminophen products announcing its plans to lower the...

2011-07-22 14:48:37

A new study by researchers at Drexel University's School of Public Health suggests that abuse of prescription painkillers may be an important gateway to the use of injected drugs such as heroin, among people with a history of using both types of drugs. The study, published in the International Journal of Drug Policy, explores factors surrounding young injection drug users' initiation into the misuse of opioid drugs. Common factors identified in this group included a family history of drug...

2011-07-22 00:01:00

Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Hydrocodone Bitartrate and Acetaminophen Oral Solution, 7.5mg / 325mg per 5mL, the generic version of Hycet® Oral Solution distributed by FSC Laboratories, Inc. Coral Springs, Florida (PRWEB) July 21, 2011 Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Hydrocodone...